Nasdaq Boardvantage
Enterprise director wants clearer permission visibility and simpler access management
Source: Autobound Signal API · 126 signals tracked for Nasdaq · updated
Get Nasdaq's live signals in Claude or ChatGPT, or by API
What changed at Nasdaq this week? Use Autobound signals for nasdaq.com.What happened
A reviewer at a 1000+ employee medical devices enterprise says managing access to Board and committee materials is cumbersome, and it is often unclear why a director can or cannot access certain materials. They call for greater permission visibility as a significant improvement. No numbers are given.
Source
From the reviews
- 3.5 of 5
“Permissions are one of the more frustrating aspects of BoardVantage. Managing access to Board and committee materials can be cumbersome, and it is not always clear why a director can or cannot access certain materials. Greater visibility into permissions and a simpler way to manage access would be a significant improvement.”
Verified User in Medical Devices, Enterprise (> 1000 emp.)Oct 27, 2026View
Extracted by Autobound
From the Signal API record- Signal
- Reliability issues
What this signalsReview themes often show where customers may look for an alternative.
- Product
- Nasdaq Boardvantage
- Star rating
- 3.5 of 5
- Reviewer
- Verified User in Medical Devices
- Reviewer details
- Enterprise (> 1000 emp.)
More from Nasdaq
- PatentsNasdaq, Inc.'s patent output is slowing: 35 grants in the past year, 2 in the past 30 days.Patents
- Web trafficnasdaq.com shows sustained decline with 3 consecutive months of decreases, down 16% overall to 5M.Web traffic
- LinkedInNasdaq recaps Technology of the Future 2026 on AI and extended trading infrastructure.LinkedIn
- GlassdoorEngineering staff request flexibility regarding current office attendance requirementsGlassdoor
- LaunchNasdaq Invests in Always-On MarketsLaunch
- 8-KNasdaq elects former Ericsson CEO Börje Ekholm to board as Holden Spaht resigns8-K
More product review signals at other companies
- Product reviewsElevenLabsHead of engineering at small company reports voice-agent interruption handling needs extra integration workProduct reviews
- Product reviewsSandboxAQEnterprise reviewers report custom scripting needed to connect models to existing data pipelinesProduct reviews
- Product reviewsTemporalHead of Engineering at a 50-person company flags steep learning curve and debugging frictionProduct reviews
The full record
From the Signal API recordDetails
- Reviewer role
- Enterprise user (Medical Devices)
Extraction
- Detected
- Nov 11, 2026
- signal_type
product-reviews- signal_subtype
ReliabilityIssues
Use this data
Get every product review signal for Nasdaq and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Nasdaq this week?”
Send it to your own tools
The Signal API returns product review signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full product-reviews record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/649bc940-690e-456b-9a41-7291f02206db returns this record as JSON. POST /v1/companies/enrich returns every signal for nasdaq.com.
{
"signal_id": "649bc940-690e-456b-9a41-7291f02206db",
"signal_type": "product-reviews",
"signal_subtype": "ReliabilityIssues",
"detected_at": "2026-11-11T11:58:28.947+00:00",
"company": {
"name": "Nasdaq",
"domain": "nasdaq.com"
},
"data": {
"summary": "A reviewer at a 1000+ employee medical devices enterprise says managing access to Board and committee materials is cumbersome, and it is often unclear why a director can or cannot access certain materials. They call for greater permission visibility as a significant improvement. No numbers are given.",
"evidence": [
{
"quote": "Permissions are one of the more frustrating aspects of BoardVantage. Managing access to Board and committee materials can be cumbersome, and it is not always clear why a director can or cannot access certain materials. Greater visibility into permissions and a simpler way to manage access would be a significant improvement.",
"review_url": "https://www.g2.com/products/nasdaq-boardvantage/reviews#review-13873463",
"review_date": "2026-10-27",
"star_rating": 3.5,
"reviewer_name": "Verified User in Medical Devices",
"reviewer_title": "Enterprise (> 1000 emp.)"
}
],
"headline": "Enterprise director wants clearer permission visibility and simpler access management",
"relevance": 55,
"product_name": "Nasdaq Boardvantage",
"source_page_url": "https://www.g2.com/products/nasdaq-boardvantage/reviews/reviews",
"switching_intent": {
"urgency": "none",
"detected": false
},
"quantified_impact": {
"has_numbers": false
},
"decision_maker_complaint": {
"title": "Enterprise user (Medical Devices)",
"is_decision_maker": false
}
}
}
curl https://signals.autobound.ai/v1/signals/649bc940-690e-456b-9a41-7291f02206db \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"nasdaq.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.